Iopofosine i-131 is under clinical development by Cellectar Biosciences and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma. According to GlobalData, Phase I drugs for Pediatric Diffuse Intrinsic Pontine Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Iopofosine i-131 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Iopofosine i-131 overview
Iopofosine I-131 (CLR-131) is under development for the treatment of waldenstrom macroglobulinemia, refractory and relapsed multiple myeloma, chronic lymphocytic leukemia, Hodgkin lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma (LPL), central nervous system lymphoma, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), solid tumors, neuroblastoma, pediatric diffuse intrinsic pontine glioma, sarcomas including rhabdomyosarcoma, Ewing's sarcoma, osteosarcoma, lymphomas and malignant brain tumors, high-grade glioma, diffuse large B-cell lymphoma (DLBCL), head and neck cancer squamous cell carcinoma. The drug candidate is radiolabeled compound administered through intravenous route in the form of solution. It comprises of PLE, 18-(p-[I-131] iodophenyl) octadecyl phosphocholine, covalently labelled with iodine-131. It is being developed based on Phospholipid Drug Conjugate (PDC) delivery platform.
It was also under development for the treatment of non-small cell lung cancer, breast cancer, soft tissue sarcoma, colorectal cancer, gastric cancer, prostate cancer, ovarian cancer and esophageal cancer.
Cellectar Biosciences overview
Cellectar Biosciences (Cellectar), is a biopharmaceutical company that discovers, develops and commercializes drugs for treatment of cancer. The company’s proprietary technology, phospholipid drug conjugates (PDC) delivery platform develops PDCs for the treatment and diagnosis of cancer. Its lead product includes CLR 131, is a small-molecule PDC, in Phase II clinical trials for the treatment of relapse or refractory multiple myeloma and B-cell lymphomas. The company is also evaluating CLR 131 in Phase I clinical trials for treatment of Pediatric patients with solid tumors, lymphomas, malignant brain tumors, head and neck cancer. Cellectar’s other products in the pipeline include CLR 1800, CLR 1900, CLR 2000, CLR 2100, CLR 2200 and CLR 12120 for solid tumors and oncology indications. The company has collaborations with Orano Med, Onconova Therapeutics, Avicenna Oncology and University of Wisconsin. Cellectar is headquartered in Florham Park, New Jersey, the US.
For a complete picture of Iopofosine i-131’s drug-specific PTSR and LoA scores, buy the report here.